Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFL-PDT vs MAL-PDT for Microinvasive Squamous Cell Carcinoma
NCT02666534Phase 1Completed
- Sponsor
- Dong-A University
- Start
- Jan 2012
- Primary completion
- Dec 2015
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of methyl aminolevulinate in squamous cell carcinoma (SCC) (2 arms), sponsored by Dong-A University. Primary endpoints: Short-term Complete Response Rate at 3 months, Long-term Complete Response Rate at 24 months and 1 more. Started Jan 2012; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT02666534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02666534.